MedICAL ADVOCATES
Children
  ARV Drug Classes
Protease Inhibitors
Nucleoside Reverse Transcriptase Inhibitors
 NNRTIs







 
Pediatric HIV Drug Main Page Pediatric HIV Main Page Home Page
Last Update:  October 27, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Protease Inhibitors
       

General Reports

          Journal Papers, Abstracts, and Commentaries

 
A WEEK IN REVIEW FEATURED REPORT
FULL-TEXT PDF ARTICLE
 Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.
 Gonzalez-Tome MI, Ramos Amador JT, et al
BMC Infect Dis. 2008 Oct 22;8(1):144
 Paper
 
Two-Year Outcomes of Children on Non-Nucleoside Reverse Transcriptase Inhibitor and
Protease Inhibitor Regimens in a South African Pediatric Antiretroviral Program.
 Jaspan HB, Berrisford AE, Boulle AM.   
Pediatr Infect Dis J. 2008 Sep 24.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Neurodevelopmental Functioning in HIV-Infected Infants and Young Children Before and After the
Introduction of Protease Inhibitor-Based Highly Active Antiretroviral Therapy.
 Lindsey JC, Malee KM, Brouwers P, Hughes MD.
Pediatrics. 2007 Feb 12;
 Abstract
 
Protease Inhibitor Combination Therapy, Severity of Illness, and Quality of Life Among
Children With Perinatally Acquired HIV-1 Infection.
Storm DS, Boland MG, Gortmaker SL, et al
 Pediatrics. 2005 Jan 3
 Abstract

Endocrinologic and immunologic factors associated with recovery of growth in children
with human immunodeficiency virus type 1infection treated withprotease inhibitors.
Van Rossum AM, Gaakeer MI, Verweel S , et al 
 Pediatr Infect Dis J 2003 Jan;22(1):70-6
Abstract		  
     
  Protease inhibitor therapy in HIV-infected children.
Feingold AR, Rutstein RM, Meislich D, et al.
AIDS Patient Care STDS 2000 Nov;14(11):589-93
 Abstract		  

Efficacy

          Journal Papers, Abstracts, and Commentaries

  Long-term protease inhibitor-containing therapy results in limited improvement in T cell
function but not restoration of interleukin-12 production in pediatric patients with aids.
Chougnet C Jankelevich S, Fowke K , et al
J Infect Dis 2001 Jul 15;184(2):201-5
Abstract

           Conference Reports, Abstracts, and Posters 

  Compared to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI), Protease Inhibitor (PI)
Containing Regimens Results in Greater Immune Reconstitution (IR) in Children Failing
Antiretroviral Therapy (ART)
C. RODRIGUEZ, J. LUJAN , M. GHOTIKAR, et al
(45 ICAAC}
 Abstract

Adverse Events

         Journal Papers, Abstracts, and Commentaries

  Endocrinologic and immunologic factors associated with recovery of growth in children
with human immunodeficiency virus type 1infection treated with protease inhibitors.
Van Rossum AM, Gaakeer MI, Verweel S , et al 
 Pediatr Infect Dis J 2003 Jan;22(1):70-6
Abstract

Metabolic abnormalities in HIV type 1-infected children treated and not treated with
protease inhibitors.
Melvin AJ, Lennon S, Mohan KM, Purnell JQ.
AIDS Res Hum Retroviruses 2001 Aug 10;17(12):1117-23
Abstract

  

           Conference Reports, Abstracts, and Posters 

  Protease-inhibitor regimen associated with hypercholesterolemia in an urban
pediatric clinic
H Levitt, R Carter, E Rillamas-Sun, et al
 (15IAC)
 Abstract

Viral Dynamics

         Journal Papers, Abstracts, and Commentaries

  Long-term protease inhibitor-containing therapy results in limited improvement in
T cell function but not restoration of interleukin-12 production in pediatric patients
with AIDS.
Chougnet C, Jankelevich S, Fowke, et al
 J Infect Dis 2001 Jul 15;184(2):201-5        
Abstract
Nucleoside Reverse Transcriptase Inhibitors
       

General Reports

          Journal Papers, Abstracts, and Commentaries
 
 
FULL TEXT PDF ARTICLE
 Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic
response to combination therapy in children (PACTG 338).
 Fiscus SA, Kovacs A, Petch LA, et al  
AIDS Res Ther. 2007 Feb 6;4(1):2
Paper

Mutations linked to drug resistance, human immunodeficiency virus type 1
biologic phenotype and their association with disease progression in children
receiving nucleoside reverse transcriptase inhibitors.
Englund JA, Raskino C, Vavro C, et al.
Pediatr Infect Dis J. 2004 Jan;23(1):15-22
 Abstract
 
         Conference Reports, Abstracts, and Posters 
 
  Treatment outcome of non-nucleoside reverse transcriptase (NNRTI)-based
highly active antiretroviral therapy (HAART) in orphans living in HIV-positive
family-style Thai community
A Siripong, O Tulloch, M Boyd, et al
 (15IAC)
Abstract
 
Resistance

         Journal Papers, Abstracts, and Commentaries

  Resistance to dual nucleoside reverse-transcriptase inhibitors in children
infected with HIV clade A/E.
Lolekha R, Sirivichayakul S, Siangphoe U,et al 
Clin Infect Dis. 2005 Jan 15;40(2):309-12.
 Abstract
Non-Nucleoside Reverse Transcriptase Inhibitors
       

General Reports

          Journal Papers, Abstracts, and Commentaries
 
 
Two-Year Outcomes of Children on Non-Nucleoside Reverse Transcriptase Inhibitor and
Protease Inhibitor Regimens in a South African Pediatric Antiretroviral Program.
 Jaspan HB, Berrisford AE, Boulle AM.   
Pediatr Infect Dis J. 2008 Sep 24.
 Abstract

Pediatric HIV Drug Main Page Pediatric HIV Main Page Home Page

Photographer: Lutheran World Relief  Photo courtesy of M/MC Photoshare at www.jhuccp.org/mmc  and  is protected by current copyright law 
Pediatric HIV Drug Classes